The effectiveness of olmesartan on inflammation at cardiopulmonary bypass

özgüler, ibrahim murat; Üstünel, Latif

doi:: 10.5455/annalsmedres.2020.04.305

The effectiveness of olmesartan on inflammation at cardiopulmonary bypass

İbrahim Murat ÖZGÜLER, (Fırat Üniversitesi Hastanesi, Tıp Fakültesi, Kalp Damar Cerrahisi Anabilim Dalı, Elazığ, Türkiye)

Latif ÜSTÜNEL (Fırat Üniversitesi Hastanesi, Tıp Fakültesi, Kalp Damar Cerrahisi Anabilim Dalı, Elazığ, Türkiye)

Annals of Medical Research

2 0

Yıl: 2021 Cilt: 28 Sayı: 1 Sayfa Aralığı: 31 - 36 Metin Dili: İngilizce DOI: : 10.5455/annalsmedres.2020.04.305 İndeks Tarihi: 28-06-2021

The effectiveness of olmesartan on inflammation at cardiopulmonary bypass

Öz:

Aim: Systemic inflammatory response syndrome may develop after coronary artery bypass graft surgery that performed by cardiopulmonary bypass technique. It is known that olmesartan, an angiotensin II receptor blocker, has anti-inflammatory effects. The antiinflammatory efficacy of olmesartan treatment was investigated in patients undergoing cardiopulmonary bypass.Materials and Methods: The study included 50 patients (14 female, 36 male) between 30-80 years of age were underwent CABG surgery. Patients were randomly assigned to control (Group C) and olmesartan (Group O) gruoups. Group O were treated with a single dose of 10 mg per day; 5 days preoperatively and 35 days postoperatively, 30 mg at the operation day. Samples were taken before the induction of anesthesia (T1), 5 minutes before cross clamping (T2), 5 minutes after cross clamping (T3), after protamine infusion (T4), postoperative day 3 (T5) and postoperative day 35 (T6) for total serum levels of IL-6, IL-10 and IL-18; for h-CRP levels preoperative (T1) and postoperative day 35 (T2).Results: Statistically significant decrease of CRP levels were observed on the postoperative 35th day in Group O (p<0.05). Statistically significant decrease of IL-6 levels were observed in the Group O after protamine infusion (T4) and postoperative 3rd day (T5) (p <0.05).There was a statistically significant increase at 5 min. after the cross declamping time (T3) for IL-10 levels (p<0.05).Conclusion: Although the anti-inflammatory efficacy of olmesartan has been proven, it can be accomplished by combining it with drugs that have anti-inflammatory effects like statins or dose increasing.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Schwartz D, Taberdel Y, Presier JC, et al. Does aprotinin influence the inflammatory response to cardiopulmaonary bypass in patients? J Thorac Cardiovasc Surg 2003;125:184-90.
2. Laffey JG, Boylan JF, Cheng DHC. The systemic inflammatory response to cardiac surgery. Anesthesiology 2002;199:215-52.
3. Paperalla D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiolgy and treatment. An update. Eur J Cardiothorac Surg 2002;21:232-44.
4. Hornick P, Taylor KM. Immune and inflammatory responses after cardiopulmonary bypass. In: Gravlee GP, Davis RF, Kurusz M, et al. Eds. Cardiopulmonary bypss: practice and principles, 2nd ed. Philadelphia: Lippincott Williams & Wilkins 2000:303-10.
5. Brix-Christensen V. The systemic Inflammatory response after cardiac surgery with cardiopulmonary bypass in children. Acta Anaesthesiol Scand 2001;45:671-9.
6. El Azab SR, Roseel PM, de Lange JJ, et al. Dexamethasone decreases the pro-to antiinflammatory cytokine ratio during cardiac surgery. Br J Anaesth 2002;88:496-501.
7. Giomarelli P, Scolletta S, Borelli E, et al. Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10. Ann Thorac Surg 2003;76:117-23.
8. Proudfoot JM, Croft KD, Puddey IB, et al. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1. J Pharmacol Exp Ther 2003;305:846-53.
9. Sherwood ER, Toliver-Kinsky T. Mechenisms of inflammatory response. Best Practice Research Clinical Anesthesiolgy 2004;18:385-405.
10. Kirshfink M. Controlling the complement system in inflammation. Immunopharmacology 1997;38:51-62.
11. Wan S, Yim AP. Cytokines in myocardial injury: impact on cardiac surgical approach. Eur J Cardiothorac Surg 1999;16:107-11.
12. Oppenheim JJ and Saklatvala J. Clinical Applications of Cytokines. (ed J.J. Oppenheim J, Rossio L and Geraing J.H.) Oxford UniversityPres, Newyork 1993: 3-15.
13. Teranishi T, Hirano T, Arima N, et al. Human helper T cell factor(s) (ThF), II: induction of IgG production in B lymphoblastoid cell lines and identification of T cell-replacing factor- (TRF) like factor(s). J Immunol 1982;128:1903-8.
14. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998;101:311-20.
15. Fickenser H, Hor S, Kupers H, et al. The IL-10 family of cytokines. Trends Immunol 2002;23:89-96.
16. Andrew Dp, Chang MS, McNinch J. CC Chemokine Acts Specifically on Chronically Activated Th2 Lymphocytes and is Produced by monocytes on Stimulation with Th2 Cytokines IL-4 and IL-13. Immunol 1998;161: 5027-38.
17. Ghayur T, Banerjee S, Hugunin M, et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 1997;386:619-23.
18. Tone M, Thompson SA, Tone Y, et al. Regulation of IL- 18 (IFN-gamma-inducing factor) gene expression. J Immunol 1997;159:6156-63.
19. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C reactive protein for the targeting of statin theraphy in the primary prevention of acute coronary events. N. Eng J Med 2001;344:1959-65.
20. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinojen, homocysteine, lipoprotein(a), and Standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.
21. Lin TC, Li CY, Tsai CS, et al. Neutrophilmediated secresyon and activasyon of matrixmetalloproteinase-9 during cardiac syrgery with cardiopulmonary bypass. surgery with cardiopulmonary bypass. Anesth Analg 2005;100:1554-60.
22. Franke A, Lante W, Fackeldy V, et al. Proinflammatory cytokines after cardiac operation: Different cellular soures at different times. Ann Thorac Surg 2002;74:363-71.
23. Mizuno M, Sada T, Kato M. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995;285:181-8.
24. Sarıbülbül O. Açık kalp makinası ve ekstrakorporeal dolaşım. Duran E editör. Kalp ve Damar Cerrahisi. İstanbul: Çapa Tıp Kitabevi 2004;75:1047-74.
25. Heidemann J, Ogawa H, Dwinell MB, et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 2003;278:8508-15.
26. Shames RS, Kishiyama JL. Bağışıklık sistemi hastalıkları. (Çevir: Avcı AB). Hastalıkların Patofizyolojisi (Ed: McPee S. çeviri Ed: Çoban E, Süleymanlar G.), 4. baskı 2006:31-57.
27. H.Argania, A.Ghorbanihaghjob, M.Aghaeishahsavarib, et al. Effects of Losartan and Enalapril on High- Sensitivity C-Reactive Protein and Total Antioxidant in Renal Transplant Recipients With Renin-Angiotensin System Polymorphisms. Transplantation Proceedings 2008;40:16-21.
28. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110:1103-7.
29. Heinzel FP, Hujer AM, Ahmed FN, et al. In vivo production and function of IL-12 p40 homodimers. J Immunol 1997;158:4381-8.
30. Ozguler IM, Burma O, Uysal A, et al. Rosuvastatin lowers systemic inflammatory response in coronary artery bypass graft accompanied by cardiopulmonary bypass surgery: A randomised controlled study. Clin Invest Med 2015;38:154-63.

APA	özgüler i, Üstünel L (2021). The effectiveness of olmesartan on inflammation at cardiopulmonary bypass. , 31 - 36. : 10.5455/annalsmedres.2020.04.305
Chicago	özgüler ibrahim murat,Üstünel Latif The effectiveness of olmesartan on inflammation at cardiopulmonary bypass. (2021): 31 - 36. : 10.5455/annalsmedres.2020.04.305
MLA	özgüler ibrahim murat,Üstünel Latif The effectiveness of olmesartan on inflammation at cardiopulmonary bypass. , 2021, ss.31 - 36. : 10.5455/annalsmedres.2020.04.305
AMA	özgüler i,Üstünel L The effectiveness of olmesartan on inflammation at cardiopulmonary bypass. . 2021; 31 - 36. : 10.5455/annalsmedres.2020.04.305
Vancouver	özgüler i,Üstünel L The effectiveness of olmesartan on inflammation at cardiopulmonary bypass. . 2021; 31 - 36. : 10.5455/annalsmedres.2020.04.305
IEEE	özgüler i,Üstünel L "The effectiveness of olmesartan on inflammation at cardiopulmonary bypass." , ss.31 - 36, 2021. : 10.5455/annalsmedres.2020.04.305
ISNAD	özgüler, ibrahim murat - Üstünel, Latif. "The effectiveness of olmesartan on inflammation at cardiopulmonary bypass". (2021), 31-36. https://doi.org/: 10.5455/annalsmedres.2020.04.305

APA	özgüler i, Üstünel L (2021). The effectiveness of olmesartan on inflammation at cardiopulmonary bypass. Annals of Medical Research, 28(1), 31 - 36. : 10.5455/annalsmedres.2020.04.305
Chicago	özgüler ibrahim murat,Üstünel Latif The effectiveness of olmesartan on inflammation at cardiopulmonary bypass. Annals of Medical Research 28, no.1 (2021): 31 - 36. : 10.5455/annalsmedres.2020.04.305
MLA	özgüler ibrahim murat,Üstünel Latif The effectiveness of olmesartan on inflammation at cardiopulmonary bypass. Annals of Medical Research, vol.28, no.1, 2021, ss.31 - 36. : 10.5455/annalsmedres.2020.04.305
AMA	özgüler i,Üstünel L The effectiveness of olmesartan on inflammation at cardiopulmonary bypass. Annals of Medical Research. 2021; 28(1): 31 - 36. : 10.5455/annalsmedres.2020.04.305
Vancouver	özgüler i,Üstünel L The effectiveness of olmesartan on inflammation at cardiopulmonary bypass. Annals of Medical Research. 2021; 28(1): 31 - 36. : 10.5455/annalsmedres.2020.04.305
IEEE	özgüler i,Üstünel L "The effectiveness of olmesartan on inflammation at cardiopulmonary bypass." Annals of Medical Research, 28, ss.31 - 36, 2021. : 10.5455/annalsmedres.2020.04.305
ISNAD	özgüler, ibrahim murat - Üstünel, Latif. "The effectiveness of olmesartan on inflammation at cardiopulmonary bypass". Annals of Medical Research 28/1 (2021), 31-36. https://doi.org/: 10.5455/annalsmedres.2020.04.305